CLAIMS

What is claimed is

1. Use of a HPV vaccine composition in the manufacture of a medicament for treatment of a cancer in a patient, wherein the cancer is selected from the group consisting of squamous cell carcinoma, basal cell carcinoma, and HPV-associated cancerous tumor or lesion, wherein the HPV vaccine is selected from the group consisting of HPV quadrivalent (types 6, 11, 16, and 18) recombinant vaccine and is substantially free of host-cell early antigen, E6 or E7, and wherein:

    a) a first dose of the HPV vaccine composition which is free of host-cell peptide, polypeptide, or protein or a degradant product thereof is to be administered to a patient 27 years of age or older or a patient previously not immunized with an HPV vaccine;

    b) a second dose of the HPV vaccine composition is to be administered to the patient in one month to three months after the first administration; and

    c) a third dose of the HPV vaccine composition is to be administered to the patient in five months to seven months after the first dose.

2. The use according to claim 1 wherein the second dose of HPV vaccine is to be administered in two months after the first dose is to be administered and the third dose of HPV vaccine is to be administered in six months after the first dose is to be administered.

3. The use according to claim 1 wherein the HPV quadrivalent (types 6, 11, 16, and 18) recombinant vaccine comprises HPV L1 proteins and HPV multivalent (types 16, 18, 31, 33, 45, 52, and 58) recombinant vaccine comprising HPV L1 proteins.

4. The use according to claim 1 wherein the treatment does not comprise or excludes an additional or other immunostimulant or adjuvant to be administered.

5. The use according to claim 1 wherein the size of the cancer is reduced.

6. The use according to claim 1 wherein the cancer is eliminated.

7. The use according to claim 1 whereby the incidence of recurrence of the cancer is reduced.

8. The use according to claim 1 wherein each dose of the HPV vaccine is 0.5 ml.

9. The use according to claim 1 characterized by

establishing a positive diagnosis of cancer prior to the first dose of HPV vaccine to be administered.

10. Use of a HPV vaccine composition in the manufacture of a medicament for the treatment of a cancer in a patient, wherein the cancer is selected from the group consisting of squamous cell carcinoma, basal cell carcinoma, and HPV-associated cancerous tumor or lesion, wherein the HPV vaccine is selected from the group consisting of HPV quadrivalent (types 6, 11, 16, and 18) recombinant vaccine, and wherein:

a) a first dose of the HPV vaccine composition is to be administered directly to the cancer site or an area immediately surrounding the cancer site; and

b) a second dose of the HPV vaccine composition is to be administered in one month to three months after the first dose is to be administered and a third dose of the HPV vaccine composition is to be administered in five months to seven months after the first dose is to be administered.

11. The use according to claim 10, further comprising:

c) the second dose of the HPV vaccine composition to be administered directly to the cancer site or an area immediately surrounding the cancer site in two months after the first dose is to be administered; and

d) optionally, the third dose of the HPV vaccine composition to be administered directly to the cancer site or an area immediately surrounding the cancer site in six months after the first dose is to be administered.

12. The use according to claim 10 wherein the cancer is eliminated or reduced in size.

13. The use according to claim 10 whereby the incidence of recurrence of the cancer is reduced.

14. The use according to claim 10 wherein the dose of the HPV vaccine administered is 0.5 ml.

15. The use according to claim 10 characterized by

establishing a positive diagnosis of cancer prior to the first dose of the HPV vaccine to be administered.

16. The use according to claim 10 wherein the vaccine is to be administered by injection.

17. The use according to claim 10 wherein the treatment does not comprise or excludes an additional or other immunostimulant or adjuvant to be administered.

18. Use of a HPV vaccine composition in the manufacture of a medicament for the treatment of a cancer in a patient, wherein the cancer is selected from the group consisting of squamous cell carcinoma, basal cell carcinoma, and HPV-associated cancerous tumor or lesion, wherein the HPV vaccine is selected from the group consisting of HPV quadrivalent (types 6, 11, 16, and 18) recombinant vaccine and is substantially free of host-cell early antigen, E6 or E7, and wherein:

a) a first dose of the HPV vaccine composition comprising at least one viral L1 protein which is free of non-L1 viral peptide, polypeptide, or protein or a degradant product thereof is to be administered to a patient having squamous cell carcinoma, basal cell carcinoma, HPV-associated cancerous tumor, or HPV-associated cancerous tumor or lesion, and being 27 years of age or older or a patient previously not immunized with a HPV vaccine;

b) a second dose of the HPV vaccine composition is to be administered to the patient in one month to three months after the first administration; and

c) a third dose of the HPV vaccine composition is to be administered to the patient in five months to seven months after the first dose.

19. The use according to claim 18 wherein the second dose of HPV vaccine is to be administered in two months after the first dose is to be administered and the third dose of HPV vaccine is to be administered in six months after the first dose is to be administered.

20. The use according to claim 18 wherein the HPV quadrivalent (types 6, 11, 16, and 18) recombinant vaccine comprises HPV L1 proteins and HPV multivalent recombinant vaccine comprising HPV L1 proteins of HPV types 16, 18, 31, 33, 45, 52, and 58.

21. The use according to claim 18 wherein the treatment does not comprise or excludes a second composition comprising an immunostimulant or an adjuvant to be administered.

22. Use of a HPV vaccine composition in the manufacture of a medicament for the treatment of a cancer in a patient, wherein the cancer is selected from the group consisting of squamous cell carcinoma, basal cell carcinoma, and HPV-associated cancerous tumor or lesion, wherein the HPV vaccine is selected from the group consisting of HPV quadrivalent (types 6, 11, 16, and 18) recombinant vaccine and is substantially free of host-cell early antigen, E6 or E7, and wherein:

a) a first dose of the HPV vaccine composition is to be administered to a patient with squamous cell carcinoma, basal cell carcinoma, HPV-associated cancerous tumor, or HPV-associated cancerous tumor or lesion, wherein the HPV vaccine composition is to be administered directly to the site or an area immediately surrounding the site of the squamous cell carcinoma, basal cell carcinoma, HPV-associated cancerous tumor or lesion; and

b) a second dose of the HPV vaccine composition is to be administered in one to three months after the first dose is to be administered and a third dose of the HPV vaccine composition is to be administered in five months to seven months after the first dose is to be administered.

23. The use according to claim 22, further comprising:

c) the second dose of the HPV vaccine composition to be administered directly to the site or an area immediately surrounding the site of the squamous cell carcinoma, basal cell carcinoma, HPV-associated cancerous tumor or lesion, in two months after the first dose is to be administered; and

d) optionally, the third dose of the HPV vaccine composition to be administered directly to site or an area immediately surrounding the site of the squamous cell carcinoma, basal cell carcinoma, HPV-associated cancerous tumor or lesion in six months after the first dose is to be administered.

24. The use according to claim 22 wherein the squamous cell carcinoma, basal cell carcinoma, HPV-associated cancerous tumor, and HPV-associated cancerous tumor or lesion is eliminated or reduced in size.

25. The use according to claim 22 whereby recurrence of cancer is reduced.

26. The use according to claim 22 wherein the vaccine is to be administered by injection.

27. The use according to claim 22 wherein the treatment does not comprise or excludes to be administered a second composition comprising an immunostimulant or adjuvant.